Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of microcystin-RR in preparing drugs for preventing or treating renal fibrosis diseases

A technology of microcystin and renal fibrosis, applied in the field of medicine, can solve the problems of lack of clinical drugs and achieve the effects of inhibiting proliferation, reducing deposition, good intervention and therapeutic effect

Active Publication Date: 2020-12-29
NANJING UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Blocking the activation of TGF-β / Smad signaling molecules and inhibiting the differentiation of myofibroblasts is an important strategy for the treatment of renal fibrosis, but so far there is still a lack of satisfactory clinical drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of microcystin-RR in preparing drugs for preventing or treating renal fibrosis diseases
  • Use of microcystin-RR in preparing drugs for preventing or treating renal fibrosis diseases
  • Use of microcystin-RR in preparing drugs for preventing or treating renal fibrosis diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0035] Experimental animals: C57 BL / 6 male mice (SPF grade), about 8 weeks old (weight 20-24 g), provided by the Institute of Model Animals, Nanjing University. Feeding conditions: well-ventilated 20°C constant temperature control, 12 hours of light / dark alternation, feeding and providing sufficient mouse food and drinking water (free intake of mice). The experimental protocol was approved by the Experimental Animal Welfare Ethics Committee of Nanjing University.

[0036] Microcystin-RR was purchased from Alexis Biochemicals (Lausen, Switzerland).

[0037] The mouse renal fibrosis animal model induced by unilateral ureteral obstruction (UUO) is a commonly used animal model in domestic and foreign academic circles for the study of the mechanism of renal fibrosis, intervention molecules and therapeutic drugs. The UUO model is stable, the histopathological features are clear, and the mechanism of occurrence is deeply understood, which is similar to the molecular basis of human r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a medical use of natural cyclic heptapeptide molecule microcystin-RR in preventing and treating renal fibrosis diseases. The verified microcystin-RR is themicrocystinof which the second and fourth amino acids of the cyclic heptapeptide structure are arginine. The microcystin RR has prevention and treatment effects on pathogenesis of the renal fibrosis caused by ureteral obstruction. Microcystin RR intervention can change kidney tissue microenvironment caused by the ureteral obstruction, inhibit fibroblast-myofibroblast differentiation (FMD) of kidney tissue cells and generate an anti-renal fibrosis medical effect.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular, the invention relates to the use of microcystin-RR in the preparation of medicines for preventing or treating human renal fibrosis. Background technique [0002] Chronic kidney disease (CKD) is a common disease that seriously threatens human health and life, with a high incidence rate of about 7-12% in different regions of the world. The renal structural and functional damage in patients with chronic kidney disease gradually aggravates over time, and clinical treatment options are very limited. In most cases, end-stage renal failure with renal fibrosis (RF) as the main pathological feature inevitably occurs. Functional failure, clinical need for life-long dialysis or kidney transplantation to maintain life. [0003] The etiology of chronic kidney disease-renal fibrosis is complex, involving genetic susceptibility, environment (infection, poison) and internal factors of the body, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/12A61P13/12
CPCA61K38/12A61P13/12
Inventor 王亚平任岩徐力致王洁
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com